Sarepta Therapeutics Inc.


Analysts Say Buy Sarepta Therapeutics Inc (SRPT) Shares, Ignore Patient Deaths

Sarepta shares dropped 4% after patient deaths revealed in the FDA FAERS database.

Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial

Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.

William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)

Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys …

Sarepta Therapeutics Inc’s (SRPT) Earnings Trigger Price Target Boost; Shares Soar 18%

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring nearly 18% in pre-market trading Thursday, after the …

Sarepta Therapeutics Inc (SRPT) Reports Q1:17 Financial Results

Sarepta Therapeutics Inc (NASDAQ:SRPT) reported financial results for the first quarter of 2017. “The first …

Sarepta Therapeutics Inc (SRPT): Will Payors Reimburse Exondys 51?

Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc …

Oppenheimer Stays Bullish on Sarepta Therapeutics Inc (SRPT) as the Stock Shows Signs of Weakness

Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc …